Oxford Immunotec Ltd has today announced the outcome of a recent study undertaken by Jean-Pierre Zellweger, who is recognised worldwide as an expert in TB control. The results of the study support the outcome of previous work undertaken by Jean-Paul Janssens, presented at the European Respiratory Society congress, Copenhagen in September 2005, and conclude that Oxford Immunotec’s T-SPOT.TB test is superior to the traditional Tuberculin Skin Test (‘TST’) in identifying individuals who should be treated for latent TB infection.
The Zellweger study assessed 91 people who had previously been in contact with a person infected with TB, using both the traditional TST and T-SPOT.TB. The aim of the study was to evaluate how well the results of each of the tests correlated with exposure to the infected individual. The results for T-SPOT.TB were statistically significant with a positive T-SPOT.TB result correlating strongly with prior exposure to the infected patient. The results for the TST did not correlate with exposure.
Of the cases tested, T-SPOT.TB correctly identified 14 positive infections (15% of those tested) whilst the TST identified 40 (44% of those tested) as positive. The TST identified 29 false positives, which were not confirmed by T-SPOT.TB, resulting from previous vaccination with the BCG vaccine. This finding confirms the large existing body of published data showing that the TST is confounded by prior vaccination with BCG.
Of the 11 cases identified as positive by both tests, 6 cases were identified by the TST when first performed. The remaining 5 cases were only confirmed by the TST after a second test, performed one month later.
Taking the T-SPOT.TB results as a true measure of infection, the study concluded that up to 65% of patients could have received incorrect treatment if decisions were based on the outcome of the TST. This has economic as well as health care implications.
Commenting on these findings Dr Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec said “It is clear from these results that T-SPOT.TB is superior to the traditional TST in contact tracing situations and allows accurate selection of contacts who should be treated for latent TB infection. The failure of the TST to properly distinguish between infected and healthy individuals can result in inappropriate treatments being given to large numbers of patients.”
Notes to editors: About Oxford Immunotec www.oxfordimmunotec.com
Oxford Immunotec, the T cell measurement company, is headquartered near Oxford, UK. The Company develops and sells clinical diagnostic products based on its patented T-SPOT™ technology, the first regulatory approved method for directly quantifying antigen-specific T cells. T-SPOT is a simple and extremely accurate method of studying a person’s cellular immune response to infection and can be applied to diagnose and monitor any major disease driven by a T cell response.
About T-SPOT™.TB T-SPOT TM.TB is an in vitro T cell measurement assay used for diagnosing TB disease and latent TB infection and the first product from Oxford Immunotec using the T-SPOT TM technology. The product is extremely robust in that it gives a result every time and offers unrivalled and maintained sensitivity in high risk and immunocompromised patient groups. T-SPOT TM.TB is approved for sale in Europe and is designed to replace the 115 year old tuberculin skin test. As such it offers a substantially more accurate and effective tool for controlling the spread of TB, addressing a market of £600m.
T-SPOT is a trademark of Oxford Immunotec.
Journal References Contact Tracing using a new T-cell based test – Zellweger et al - International Journal for Tuberculosis and Lung Disease 9(11):1242-1247 2005
